Acquisition Legacy Follow up opportunities stemming from the 2019 acquisition by Canopy Biosciences to approach the new parent organization with Core Diagnostics’ biomarker analysis capabilities and integration potential for their portfolio of biopharma research services.

Niche Biomarker Services Target biotech and pharma clients needing biomarker analysis across early research to Phase III trials, highlighting Core Diagnostics’ molecular testing, FISH, mutational, expression analyses, and IHC capabilities as a cost-effective outsourced lab partner.

Low Revenue levers Leverage their current revenue under one million to pursue value-based collaborations, pilot studies, and LDT or IVD assay development contracts with mid-market biotechs seeking CRO-like biomarker services without large-scale lab commitments.

Strategic Partnerships Position as an extension-of-client lab for biotech companies developing assays, offering scalable QMS-compliant pathology and molecular testing workflows, and seamless integration with client teams to accelerate assay validation and data generation.

Competitive Positioning Differentiate from larger CROs by emphasizing flexibility, specialized esoteric pathology capabilities, and personalized service for biomarker projects, targeting clients who require rapid turnaround, bespoke assay development, and closer collaboration.